Get the Stockscreener App
30.16
4.95%
-1.57
After Hours:
30.16
Arrivent Biopharma Inc stock is traded at $30.16, with a volume of 759.26K.
It is down -4.95% in the last 24 hours and down -11.29% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
See More
Previous Close:
$31.73
Open:
$31.86
24h Volume:
759.26K
Relative Volume:
1.38
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-166.31M
P/E Ratio:
-6.762
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
+6.87%
1M Performance:
-11.29%
6M Performance:
+30.51%
1Y Performance:
+42.40%
1-Day Range:
$30.00
$32.44
1-Week Range:
$27.40
$33.01
52-Week Range:
$16.10
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
30.16 | 1.48B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
AVBP|Arrivent Biopharma Inc|Price:30.140|Chg%:-1.590 - TradingKey
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AVBP|Arrivent Biopharma Inc|Price:31.730|Chg%:+0.190 - TradingKey
TradingKey - TradingKey
ArriVent BioPharma, Inc. Revenue Breakdown – NASDAQ:AVBP - TradingView
AVBP|Arrivent Biopharma Inc|Price:32.020|Chg%:+0.480 - TradingKey
(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
ArriVent BioPharma (AVBP) Edges Lower, Holding Above Key Support as Consolidation ContinuesLarge Cap Trends - dars.gov.et
ArriVent BioPharma (AVBP) Edges Lower, Testing Support Amid Biotech VolatilityDefined Outcome ETF - dars.gov.et
ArriVent BioPharma Q1 2026 Earnings: EPS Miss Reflects Increased R&D Spending; Shares Edge HigherCEO Earnings Statement - dars.gov.et
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target - TipRanks
AVBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AVBP Q1 2026 Earnings: EPS Miss Highlights Development Stage ChallengesEPS Growth Rate - DonanımHaber
ArriVent BioPharma (AVBP) Edges Lower Amid Consolidation Near Key LevelsPCR Divergence - dars.gov.et
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
ArriVent BioPharma (AVBP) Posts Modest Gain at $34.0, Hovers Near ResistancePrice Momentum Stocks - dars.gov.et
Price to sales forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
AVBP Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical MilestonesCore Business Growth - dars.gov.et
AVBP 260717 5.00P (AVBP260717P5000) Stock Options Chain | Quotes & News - Moomoo
ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP) - TradingView
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
ArriVent BioPharma (AVBP) Gains 5.6% as Bullish Momentum BuildsBPI Bull Confirmed - dars.gov.et
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com - Investing.com Nigeria
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options - Stock Titan
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74 - Stock Titan
ArriVent BioPharma Stockholders Back Board and Auditor Slate - TipRanks
ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor - Stock Titan
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD - Investing.com UK
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD By Investing.com - Investing.com South Africa
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74 - Moomoo
(AVBP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AVBP: Directors were elected through 2029 and the auditor's appointment was ratified with strong support - TradingView
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):